DENVER, April 1 /PRNewswire-USNewswire/ -- Responding to President Obama's call for "a cure for cancer in our time," the Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report today on medicines in the research pipeline for cancer. The report shows that America's pharmaceutical research and biotechnology companies are testing a record 861 new cancer medicines and vaccines. The medicines listed in the report are being tested in human clinical trials or are awaiting approval by the U.S. Food and Drug Administration.
Nationwide, cancer is the second leading cause of death, affecting more than 10 million Americans, according to the National Cancer Institute. This year, more than half a million Americans are expected to die of cancer -- more than 1,500 a day. In Colorado, the lifetime risk of cancer is 1 in 2 for males and 2 in 5 for females. The most commonly diagnosed cancer in the state is breast cancer, followed by prostate and lung cancer.
"We released this report in Denver because of Colorado's growing role in developing cancer medicines," said PhRMA Senior Vice President Ken Johnson, who unveiled the report at the State Capitol Building.
"Oncology is one of Colorado's core research competencies, so the President's call to cure cancer resonates powerfully in our state," said Colorado Lt. Governor Barbara O'Brien. "We are proud that the cancer medicines now in the research pipeline in Colorado are contributing substantially to the incredible progress made in the last five years by biopharmaceutical companies in developing new and more effective cancer treatments. The nation must continue its strong commitment to the cutting-edge pharmaceutical research that will enable cancer patients to live longer, healthier, and more productive lives."
"I am one of those patients who was diagnosed with cancer and was given a new treatment that brought me from the brink of
|SOURCE Pharmaceutical Research and Manufacturers of America|
Copyright©2009 PR Newswire.
All rights reserved